Tarak Vasavada, MD
Psychiatry · Huntsville, ALNPI 1881656007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 80 payments — averaging $34.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$607
- Alkermes, Inc.$504
- AbbVie$334
- E.r. Squibb & Sons, L.L.C.$250
- Otsuka America Pharmaceutical, Inc.$178
- Neurocrine Biosciences, Inc.$177
- plus $690 from 7 others
What the payments were for
- Food & beverage$2,739100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $607 |
| Alkermes, Inc. | 16 | $504 |
| AbbVie(2 entities) | 3 | $334 |
| E.r. Squibb & Sons, L.L.C. | 5 | $250 |
| Otsuka America Pharmaceutical, Inc. | 11 | $178 |
| Neurocrine Biosciences, Inc. | 2 | $177 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $171 |
| Grifols USA, LLC | 1 | $142 |
| Novo Nordisk | 2 | $121 |
| Axsome Therapeutics, Inc. | 1 | $110 |
| UCB, Inc. | 1 | $106 |
| Indivior Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- VRAYLAR$240
- COBENFY$199
- INVEGA SUSTENNA$143
- Prolastin-C$142
- CAPLYTA$127
- ARISTADA INITIO$120
- Auvelity$110
- Briviact$106
How this compares
$2,739 in reported general payments places this provider in the 75th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 41 | $462 |
| Mirtazapine | 19 | $171 |
| Divalproex Sodium | 14 | $162 |
| Olanzapine | 13 | $136 |
| Escitalopram Oxalate | 23 | $109 |
| Risperidone | 18 | $107 |
| Sertraline Hcl | 15 | $60 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Huntsville
- Scariya KumaramangalamHuntsville$440K
- Glenn ArchibaldHuntsville$24K
- Sofia AeschlimannHuntsville$18K
- Heath PenlandHuntsville$11K
- Quratulain AghaHuntsville$10K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Mark HaygoodMobile$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.